Velsipity® ▼ (etrasimod)| Homepage

This site is intended only for healthcare professionals resident in the Republic of Ireland

Log out

Our medicines

Therapy areas

Explore content

Materials

Videos

Podcasts

3D Body Atlas

Let’s connect

Let's connect

Adverse event reporting can be found at the bottom of the page

Home

Efficacy

Efficacy Home Page

Trial Design

Clinical Remission

Early Symptomatic Response

Endoscopic Improvement

Bio/JAKi Subgroups Data

Isolated Proctitis

Safety

Adverse events

Cardiac and ocular adverse events

Getting Started

Resources

Materials

Videos

Prescribing Information

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

UC doesn't have to be chaos for your patients — Move them forward with VELSIPITY^®, the only oral advanced therapy* for patients 16 years and older with moderately to severely active UC^1-3

VELSIPITY^®can offer your patients³:

The first and only oral advanced UC therapy indicated for patients 16 years of age and older

Recommended monitoring for certain safety signals, but no unique required scheduled monitoring^†

Same dose from the start — no titration required

DISCOVER CLINICAL TRIAL DATA

Sustained, steroid-free remission^3,4
Early symptomatic response by day 2⁵
Higher rates of endoscopic improvement.
The only advanced therapy* proven in patients with isolated proctitis in phase 3 randomised clinical trials⁶

SEE THE DATA

SEE THE SAFETY PROFILE

No increased risk of serious or opportunistic infections, including herpes zoster, vs placebo⁴
Well tolerated with mostly mild to moderate adverse events and discontinuation rates similar to placebo, supported by up to 2.5 years of clinical data^4,7

SEE SAFETY

GET DOSING INFORMATION

The same dose right from the start— no titration³
Straightforward one-time testing³
Recommended monitoring for certain safety signals, but no unique scheduled monitoring required^†

GETTING STARTED

Advanced therapies include S1P receptor modulators, biologics, and JAK inhibitors.⁴

No required scheduled monitoring outside of standard clinical assessments. Safety signals should be monitored during treatment and managed appropriately, as recommended in the Summary of Product Characteristics for VELSIPITY^®

References:

Peyrin-Biroulet L, Van Assche G, Sturm A, et al. Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: a real world-based study. Dig Liver Dis. 2016;48(6):601-607.

Dubinsky MC, Watanabe K, Molander P, et al; The Global UC Narrative Survey Panel. Ulcerative Colitis Narrative global survey findings: the impact of living with ulcerative colitis—patients’ and physicians’ view. Inflamm Bowel Dis. 2021;27(11):1747-1755.

VELSIPITY^®(etrasimod) Summary of Product Characteristics. Available online at www.medicines.ie.

Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies [published correction appears in Lancet. 2023;401(10381):1000]. Lancet. 2023;401(10383):1159-1171.

Dubinsky MC, Vermeire S, Chaparro M, et al. Symptomatic improvement observed within 2 days of etrasimod induction therapy: results from ELEVATE UC 52 and ELEVATE UC 12 studies in patients with ulcerative colitis. United European Gastroenterol J. 2023;11(suppl 8):201-534. Poster presented at: 31st United European Gastroenterology (UEG) Week 2023; Oct 14-17, 2023; Copenhagen, Denmark. Abstract ID: MP359. https://onlinelibrary.wiley.com/doi/epdf/10.1002/ueg2.12460. Accessed December 18, 2023.

Peyrin-Biroulet L, Dubinsky MC, Sands BE, et al. Efficacy and safety of etrasimod in patients with moderate to severe isolated proctitis relative to those with more extensive colitis: results from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. United European Gastroenterol J. 2023;11(suppl 8):201-534. Poster presented at: 31st United European Gastroenterology (UEG) Week 2023; Oct 14-17, 2023; Copenhagen, Denmark. Abstract ID: MP429. https://onlinelibrary.wiley.com/doi/epdf/10.1002/ueg2.12460. Accessed December 18, 2023.

Vermeire S, Peyrin-Biroulet L, Panés J, et al. Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials. J Crohns Colitis. 2023;17(suppl 1):i619-i620. Abstracts of the 18th Congress of ECCO 2023—European Crohn’s and Colitis Organisation; March 1-4, 2023; Copenhagen, Denmark. Abstract ID: P490. jjac190.0620. https://academic.oup.com/ecco-jcc/article/17/Supplement_1/i619/7009929. Accessed December 18, 2023.

Legal Category S1A
Further information available on request.

PP-V1A-IRL-0024 Date of preparation February 2025

Adverse events should be reported.

If you wish to make a medical information inquiry or report an adverse event please contact Pfizer on 1800 633 363
or email Pfizer at [email protected] or visit www.PfizerMedicalInformation.ie

Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

PfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Account

Log out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.Registered in the Republic of Ireland No. 127002. Directors: M. Adamson (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.

PP-UNP-IRL-0937. July 2025

You are now leaving PfizerPro

You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0901. July 2025